IL-1B, thought to increase amyloid precursor protein
and promote tau phosphorylation, increased by 109%.
Amyloid precursor protein
(APP) severing disorder lead to over expression or less clearance of A[beta], and then A[beta] became aggregated.
Merck is evaluating verubecestat (MK-8931) an investigational small molecule inhibitor of the beta-site amyloid precursor protein
cleaving enzyme 1 (BACE1), in a Phase 3 study of people with prodromal AD (APECS).
The study assessed verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein
cleaving enzyme 1 (BACE1), in people with mild-to-moderate Alzheimer's disease.
Molecular mechanism of Amyloid Precursor Protein
One thing that scientists on both sides of the beta-amyloid debate have noticed is that beta-amyloid has what amounts to a sister protein: amyloid precursor protein
intra cellular domain, or AICD.
Because the amyloid precursor protein
gene is also over-expressed in Down syndrome, these patients accumulate beta-amyloid at a greatly accelerated rate and will, inevitably, develop Alzheimer's dementia.
The A[beta] peptide is a cleavage product of amyloid precursor protein
(APP) by sequential action of [beta]- and [gamma]-secretases which release 39-43-amino- acid peptide from the C-terminal (cytoplasmic) end of transmembrane protein .
People with Down syndrome are born with an extra copy of chromosome 21, which contains the amyloid precursor protein
It is generated when the considerably larger amyloid precursor protein
, or APP, is cleaved.
Molecular evidences show that HSV-1 infection of neuronal and glial cells results in the formation of the characteristic abnormal molecule of AD ([alpha]-amyloid) and a decrease of the amyloid precursor protein
Cleavage of the amyloid precursor protein
(APP) generates varying lengths of A3 peptides (38-43 amino acids) that accumulate in the extracellular space.